Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ABP) is a clinical-stage biopharmaceutical company that entered the public markets through its merger with CF Acquisition Corp VIII, a blank-check vehicle sponsored by Cantor Fitzgerald that completed its initial public offering in 2022. The company develops antibody-based therapeutics with programs targeting oncology and other serious diseases, operating within the life sciences and biotechnology sector. Abpro filed its most recent Form 10-Q with the SEC on July 9, 2024, reflecting its continued status as a post-merger public reporting issuer. Investors and analysts can access the full deal history, filings, and SPAC data for Abpro Holdings by signing up on SpacDesk.